ScholarIQanswers from OpenAlex
Fiona Stanley Hospital
InstitutionResearch output, impact & collaborations
Fiona Stanley Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about Fiona Stanley Hospital?
ScholarIQrecord summary
Fiona Stanley Hospital is a research organisation in Perth, AU. OpenAlex records 6,658 works and 169,511 citations for it. 1,847 researchers list it as their most recent affiliation.
How many works does Fiona Stanley Hospital have?
ScholarIQindexed works
Fiona Stanley Hospital has 6,658 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Fiona Stanley Hospital have?
ScholarIQcitation count
Fiona Stanley Hospital has 169,511 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Fiona Stanley Hospital?
ScholarIQresearcher count
Fiona Stanley Hospital has 1,847 researchers in the ScholarIQ index.
What is the average h-index at Fiona Stanley Hospital?
ScholarIQavg h-index
Fiona Stanley Hospital has an average h-index of 23 in OpenAlex.
What is the ROR of Fiona Stanley Hospital?
ScholarIQror
The ROR for Fiona Stanley Hospital is on the source record.
What is the OpenAlex record for Fiona Stanley Hospital?
ScholarIQopenalex
The OpenAlex for Fiona Stanley Hospital is on the source record.
Who are the most-cited researchers behind Fiona Stanley Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on Fiona Stanley Hospital?
ScholarIQmost cited works
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Y. Zhang, Margaret McJannett, Martin R. Stockler, John Violet, Scott Williams, Andrew Martin, Ian D. Davis, Arun Azad, Wei Chua, Ian D. Davis, Nattakorn Dhiantravan, Louise Emmett, Kate Ford, Michael S. Hofman, Roslyn J. Francis, Craig Gedye, Jeffrey C. Goh, Alex Guminski, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Siobhan Ng, David A. Pattison, Shakher Ramdave, Nisha Rana, Andrew Redfern, Natalie Rutherford, Shahneen Sandhu, Andrew M. Scott, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, John Violet, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, James P Buteau, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Yan Zhang, Martin R. Stockler, Scott Williams, Andrew Martin, Ian D. Davis, Tim Akhurst, Ramin Alipour, Dale L. Bailey, Patricia Banks, Alexis Beaulieu, Louise Campbell, Megan Crumbaker, Nattakorn Dhiantravan, Anis Hamid, Mohammad B. Haskali, Terry Hung, Grace Kong, Nick Lawrence, Jeremy Lewin, Michael McCarthy, Kate Moodie, Declan G. Murphy, Andrew Nguyen, David Pook, Aravind Ravi Kumar, Paul Roach, Peter Roselt, Javad Saghebi, Geoffrey Schembri, Lavinia Spain, Shalini Subramaniam, Sue Ping Thang, Paul Thomas, Ben Tran, Roslyn E. Wallace, Sonia Yip
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Craig Gedye, Natalie Rutherford, Shahneen Sandhu, Aravind Ravi Kumar, David Pook, Shakher Ramdave, David Nadebaum, Mark Voskoboynik, Andrew Redfern, W A Macdonald, Laurence E. Krieger, Geoffrey Schembri, Wei Chua, Peter Lin, Lisa G. Horvath, Patricia Bastick, Patrick Butler, Alison Yan Zhang, Sonia Yip, Hayley Thomas, Ailsa Langford, Michael S. Hofman, Margaret McJannett, Andrew Martin, Martin R. Stockler, Ian D. Davis
Experimental manipulation of the dawn and dusk chorus in the blackbird Turdus merula
InnesC. Cuthill, W A Macdonald
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
Arun Azad, Mathias Bressel, Hsiang Tan, Mark Voskoboynik, Aneta Suder, Andrew Weickhardt, Alexander Guminski, Roslyn J. Francis, Javad Saghebi, Nattakorn Dhiantravan, Anthony M. Joshua, Louise Emmett, Lisa G. Horvath, Declan G. Murphy, Edward Hsiao, Bavanthi Balakrishnar, Peter Lin, Andrew Redfern, W A Macdonald, Siobhan Ng, Sze-Ting Lee, David A. Pattison, David Nadebaum, Ian Kirkwood, Michael S. Hofman, T Akhurst, R Alipour, L Au, P Banks, B Emerson, N Hussain, M Haskali, J Lewin, R Linklater, L Kostos, R Kashyap, P Krishanth, G Kong, A Kumar, D Murphy, P Roselt, S Sandhu, M Scalzo, B Tran, R Wallace, L Spain, H Bourke, A Milton, D Russo, M Bills, C Chew, W Hsieh, B Crouch, D Smyth, S Pandelus, H Lam, C Gan, J Goh, A Scott, U Hafeez, U Ackermann, K Young, A Poon, K Pathmaraj, G Schembri, P Roach, D Bailey, T Hung, A Asad, T Hagan, J Watts, E Campbell, W Chua, A Pal, M Crumbaker, A Nguyen, A Yam, J Chen, L Ardolino, K Kongrak, L Ratnayake
How much of the research on Fiona Stanley Hospital is open access?
ScholarIQopen access share
36%OPEN ACCESS